title: Is Menstruation or the Serum Hormone Level a Useful Predictor for Live Birth after Gonadotropin-Releasing Hormone Agonist during Chemotherapy in Young Breast Cancer Patients.
abstract: OBJECTIVE
  The study aimed to investigate whether changes in menstruation or hormone levels are useful parameters to assess the efficacy of gonadotropin-releasing hormone (GnRH) agonist co-treatment with chemotherapy.
  
  
  METHODS
  This study included women in their reproductive age diagnosed with breast cancer and who received GnRH agonist during chemotherapy for ovarian protection. Women with treatment failure (follicle-stimulating hormone (FSH) level >20 mIU/mL after at least 12 months and failure for becoming pregnant; n = 16) or with treatment success (becoming pregnant spontaneously and having a live birth; n = 20) were selected, and clinical characteristics, resumption of menstruation, and changes in hormone profiles were compared.
  
  
  RESULTS
  Resumption of menstruation was observed in 8 (50%) women and the time until resumption was significantly longer in the treatment failure group. Although levels of luteinizing hormone (LH) and FSH at 3 and 6 months after chemotherapy did not differ between the groups, serum FSH levels were significantly higher in the treatment failure group at 12 months. However, levels of LH or estradiol were not different at each time point.
  
  
  CONCLUSIONS
  Changes in menstruation and FSH levels at 12 months or longer may be useful parameters to predict successful spontaneous pregnancy and live birth after GnRH agonist co-treatment for ovarian protection in young breast cancer patients who undergo chemotherapy.
authors.affiliation: Department of Obstetrics and Gynaecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Dong-Yun
authors.initials: DY
authors.lastname: Lee
authors.forename: DooSeok
authors.initials: D
authors.lastname: Choi
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D004958:Estradiol / Q000097:blood*; D005260:Female; D059247:Fertility Preservation / Q000379:methods; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008598:Menstruation / Q000502:physiology*; D010053:Ovary / Q000187:drug effects; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D017211:Treatment Failure
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
keywords: Chemotherapy; Gonadotoxicity; Gonadotropin-releasing hormone agonist; Ovarian protection